Dreyer’s adds snack-size frozen delights to portfolio
NEW YORK — Dreyer’s, which is owned by Nestlé, has introduced snack-size frozen treats.
New Dreyer’s Slow Churned light ice cream now is available in snack-size cups, serving ice cream lovers half the fat and one-third less calories, the brand said. Additionally, the snack-size cups also will be available for its frozen yogurt blends line, which contains live and active cultures that may aid a healthy digestive system, Dreyer’s added.
Another ice-cold treat is Dreyer’s snack-size fruit bars, which tout 50 calories per serving and are available in a variety of flavors, including new pomegranate and acai blueberry. The 1.5-oz. snack-size bars contain real fruit and vitamin C.
Dreyer’s products are available in the frozen food section of grocery stores nationwide.
Mott’s Garden Blend targets adults
NEW YORK — In an effort to get adults to consume their daily serving of vegetables, Mott’s has introduced a 100% juice blend.
New Mott’s Garden Blend offers two servings of vegetables, as well as vitamins A and C, in each 8-fl.-oz. glass, the company said. The product is available in original and low sodium varieties.
Mott’s Garden Blend is available for purchase at retailers nationwide.
Reckitt Benckiser posts Q2 results
SLOUGH, England — Second-quarter net revenue increased to 2.34 billion pounds ($3.83 billion) for Reckitt Benckiser, the company announced in an earnings statement Monday.
The company attributed its increases to growth in developing markets. For the quarter, RB said net revenue increased by 13% and 5% on a like-for-like basis. LFL growth excludes the impact of changes in exchange rates, major acquisitions and disposals, RB noted.
"Growth in the base business was driven in particular by an excellent result in developing markets, and was boosted by innovations, such as the continued rollout of the Dettol no-touch hand soap system into new markets, as well as a significant level of investment in media and promotional spend," Reckitt Benckiser CEO Bart Becht said.
The company said that it fears that its heroin dependency treatment Suboxone will lose its patent protection in the United States, thus opening up the market for generic competition.
"At the end of June 2011, the Suboxone film had captured a 41% volume share of the U.S. market: as a result, Suboxone tablets in the U.S. now represent less than 50% of total RBP net revenue," Becht noted.
The company added that it expects to achieve an increase of 12% for its full-year revenues.